Evidence map›Paper›PMID 36143454›Full record

ArticleLife (Basel, Switzerland)2022

Myostatin/AKT/FOXO Signaling Is Altered in Human Non-Ischemic Dilated Cardiomyopathy.

Lea Hildebrandt, Maja-Theresa Dieterlen, Kristin Klaeske, Josephina Haunschild, Diyar Saeed, Sandra Eifert, Michael A Borger, Khalil Jawad

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Lea HildebrandtDepartment of Cardiac Surgery, Heart Center, HELIOS Clinic, University Hospital Leipzig, 04289 Leipzig, Germany.ORCID 0000-0001-7487-6345
Maja-Theresa DieterlenDepartment of Cardiac Surgery, Heart Center, HELIOS Clinic, University Hospital Leipzig, 04289 Leipzig, Germany.ORCID 0000-0002-5503-9901
Kristin KlaeskeDepartment of Cardiac Surgery, Heart Center, HELIOS Clinic, University Hospital Leipzig, 04289 Leipzig, Germany.
Josephina HaunschildDepartment of Cardiac Surgery, Heart Center, HELIOS Clinic, University Hospital Leipzig, 04289 Leipzig, Germany.
Diyar SaeedDepartment of Cardiac Surgery, Heart Center, HELIOS Clinic, University Hospital Leipzig, 04289 Leipzig, Germany.
Sandra EifertDepartment of Cardiac Surgery, Heart Center, HELIOS Clinic, University Hospital Leipzig, 04289 Leipzig, Germany.
Michael A BorgerDepartment of Cardiac Surgery, Heart Center, HELIOS Clinic, University Hospital Leipzig, 04289 Leipzig, Germany.
Khalil JawadDepartment of Cardiac Surgery, Heart Center, HELIOS Clinic, University Hospital Leipzig, 04289 Leipzig, Germany.ORCID 0000-0001-7897-1462
University Hospital Leipzig · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Disturbances in the ubiquitin proteasome system, and especially changes of the E3 ligases, are subjects of interest when searching for causes and therapies for cardiomyopathies. The aim of this study was to clarify whether the myostatin/AKT/forkhead box O (FOXO) pathway, which regulates the expression of the E3 ligases muscle atrophy F-box gene (MAFbx) and muscle ring-finger protein-1 (MuRF1), is changed in dilated cardiomyopathy of ischemic origin (IDCM) and dilated cardiomyopathy of non-ischemic origin (NIDCM). The mRNA and protein expression of myostatin, AKT, FOXO1, FOXO3, MAFbx and MuRF1 were quantified by real-time polymerase chain reaction and ELISA, respectively, in myocardial tissue from 26 IDCM and 23 NIDCM patients. Septal tissue from 17 patients undergoing Morrow resection served as a control. MAFbx and FOXO1 mRNA and protein expression (all p < 0.05), AKT mRNA (p < 0.01) and myostatin protein expression (p = 0.02) were decreased in NIDCM patients compared to the control group. Apart from decreases of AKT and MAFbx mRNA expression (both p < 0.01), no significant differences were detected in IDCM patients compared to the control group. Our results demonstrate that the myostatin/AKT/FOXO pathway is altered in NIDCM but not in IDCM patients. FOXO1 seems to be an important drug target for regulating the expression of MAFbx in NIDCM patients.

Indexed as

cardiomyopathyE3 ligasesFOXOheart failureMAFbxMuRF1protein breakdown

Identifiers

PMID36143454
PMCPMC9506454
OpenAlexW4295540224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.